ReviewCancer immunology, immunotherapy : CII2011
Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.
Review in Cancer immunology, immunotherapy : CII, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Evaluating neoantigen-vaccine responses through mechanistic and model-based frameworks.NPJ precision oncology · 2026Article
- Self-Assembly of Immune Signals to Program Innate Immunity through Rational Adjuvant Design.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Optimal combination treatment regimens of vaccine and radiotherapy augment tumor-bearing host immunity.Communications biology · 2021Article
- Inhibition of colorectal cancer liver metastasis in BALB/c mice following intratumoral injection of oncolytic herpes simplex virus type 2 for the induction of specific antitumor immunity.Oncology letters · 2019Article
- Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo.Therapeutics and clinical risk management · 2017Article
- Targeted Programming of the Lymph Node Environment Causes Evolution of Local and Systemic Immunity.Cellular and molecular bioengineering · 2016Article
- NF-κB functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cells.Cell reports · 2014Article
- Gene therapy in pancreatic cancer.World journal of gastroenterology · 2014Review
- Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies.The AAPS journal · 2013Article
- Overview of cancer vaccines: considerations for development.Human vaccines & immunotherapeutics · 2012Review
- Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- What are regulatory T cells (Treg) regulating in cancer and why?Seminars in cancer biology · 2012Review
- T cells in gastric cancer: friends or foes.Clinical & developmental immunology · 2012Review
- Novel antibody-based proteins for cancer immunotherapy.Cancers · 2011Article
- The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg).Current medicinal chemistry · 2011Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Although cancer immunology has made vigorous progress over the last decade, its future remains uncertain. Tumors have clearly proved subject to immune surveillance, leading to antigenic editing, and means of activating both T and B arms of the immune system have been devised. Therapeutic vaccination and monoclonal antibody therapy have so far proved disappointing, because tumors prove adept at evasion from immune control. Dual targeting could well counteract evasion, provided that the two targets are independent and are attacked simultaneously. This stage has nearly but not quite been reached in several forms of immunotherapy, particularly of B-cell cancers, although such treatment also carries hazards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.